
    
      This is an open-label (all people know the identity of the intervention) study to assess the
      antiviral activity, safety, tolerability and pharmacokinetics (explores what the body does to
      the medication) of TMC435350 hereafter referred to as TMC435. Approximately 40 participants
      will be divided in 5 groups as per the genotype (8 participants each group). The study will
      include a screening phase (up to 6 weeks), treatment phase (7 days) and a follow-up phase
      (30-35 days after the last dose of study medication). Safety evaluations will include
      assessment of adverse events, clinical laboratory tests and cardiovascular safety.
    
  